| Bioactivity | Ubamatamab (REGN4018) is a human bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity[1]. |
| Invitro | Ubamatamab（REGN4018；0.1 pM-10 nM；48 小时）诱导人 T 细胞和猕猴 T 细胞杀死 OVCAR-3 细胞 (EC50 值分别为 13.6 pM 和 30.6 pM)[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | Ubamatamab（REGN4018；0.01-0.5 mg/kg；腹腔注射；第 6、10、13、16 和 21 天）有效抑制腹膜内卵巢肿瘤的生长[1]。Ubamatamab（REGN4018；0.01-1 mg/kg；i.p；每周一次；总共五剂）显示血清细胞因子和 C 反应蛋白有轻微和短暂的增加，没有明显的毒性[1]。 Animal Model: |
| Name | Ubamatamab |
| CAS | 2305629-50-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alison Crawford, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. |